Most sexual dysfunction treatments address the vascular side of the equation — improving blood flow to produce erections or engorgement. PT-141 takes a completely different approach: it targets melanocortin receptors in the hypothalamus and limbic system — the brain regions directly responsible for sexual desire and motivation.
This central mechanism means PT-141 works where hormones and blood-flow medications cannot fully reach: the psychological and neurological components of sexual desire. Patients with optimal testosterone levels who still struggle with libido often respond dramatically to PT-141, because their issue was never hormonal — it was neurological.
PT-141 (Bremelanotide) received FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women — making it one of the few FDA-approved treatments for female sexual dysfunction. In men, it is used off-label for libido enhancement and sexual function.
At Body Symmetry MD, we assess sexual function comprehensively — including hormones, vascular health, medications that suppress libido, and psychological factors — before designing a protocol that may include PT-141, hormone optimization, or PDE5 inhibitors depending on the root cause.